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Abstract  27 
Nitric oxide alters gastric blood flow, improves vascular function and mediates glucose uptake 28 
within the intestines and skeletal muscle. Dietary nitrate, acting as a source of nitric oxide, 29 
appears to be a potential low cost therapy that may help maintain glucose homeostasis.      30 
In a randomised, double-blind, placebo-controlled crossover study, 31 young and older adult 31 
participants had a standardised breakfast, supplemented with either nitrate rich beetroot juice 32 
(11.91 mmol nitrate) or nitrate depleted beetroot juice as placebo (0.01 mmol nitrate). MRI was 33 
used to assess apparent diffusion coefficient (ADC), portal vein flux and velocity. Plasma 34 
glucose, incretin and C-peptide concentrations and BP were assessed. Outcome variables were 35 
measured at baseline and hourly for 3 hours.  36 
Compared with a placebo, beetroot juice resulted in a significant elevation in plasma nitrate 37 
and plasma nitrite concentration. No differences were seen for the young or older adult cohorts 38 
between placebo and beetroot juice for ADC, or portal vein flux. There was an interaction 39 
effect in the young adults, between visits for portal vein velocity. Nitrate supplementation did 40 
not reduce plasma glucose active GLP-1, total GLP-1 or plasma C-peptide concentrations for 41 
the young or older adult cohorts.  42 
Despite a significant elevation in plasma nitrite concentration following an acute dose of (11.91 43 
mmol) nitrate, there was no effect on hepatic blood flow, plasma glucose, C-peptide, or incretin 44 
concentration in healthy adults.  45 
New and Noteworthy  46 
This is the first study investigating the effect dietary nitrate supplementation on hepatic blood 47 
flow, incretin and C-peptide concentrations in young and older adults. Despite a 48 
physiologically relevant elevation in plasma nitrite concentration following an acute dose of 49 
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11.9 mmol nitrate, there was no effect on hepatic blood flow, plasma glucose, C-peptide, or 50 
incretin concentration. Acute supplementation of nitrate does not appear to alter hepatic 51 
diffusion or modulate post-prandial glucose homeostasis.  52 
Introduction   53 
Nitric oxide is produced within the body via two independent pathways. The first pathway in 54 
which nitric oxide is produced is via, nitric oxide synthase enzymes (NOS), acting on the amino 55 
acid L-arginine  in an O2 dependent reaction (1). The second pathway, known as the entero-56 
salivary pathway is O2 independent. It involves nitrate from the diet being ingested, absorbed 57 
through the stomach wall and proximal small intestine (3, 19) and entering the circulation 58 
where it is concentrated in the salivary glands. A reduction of nitrate to nitrite via facultative 59 
anaerobic bacteria occurs within the mouth (18). Nitrite is then swallowed and some nitrite is 60 
converted to nitric oxide in the acidic environment of the stomach (5) whilst some of the nitrite 61 
is absorbed into the circulation and acts as a storage pool for subsequent conversion to nitric 62 
oxide (48). Elevated concentrations of nitric oxide have been shown to increase gastric blood 63 
flow (55) whilst acidified nitrite has been shown to protect against enteric pathogens (47).  64 
Another possible mechanism exists for the conversion of nitrate to nitrite, whereby hepatic 65 
xanthine oxidoreductase catalyses the reduction of nitrate to nitrite (31). This mechanism in 66 
conjunction with the uptake of nitrite into the portal circulation may explain why one of the 67 
highest concentrations of nitrite in any organ is found within the liver (10, 59). Subsequent 68 
increases in the bioavailability of nitric oxide within the liver may be expedited by a number 69 
of nitrite reductases such as; xanthine oxidoreductase (44, 50), aldehyde oxidase (39, 43), 70 
cytoglobin (11, 20, 45) and deoxyhaemoglobin (16). The potential increase of nitric oxide 71 
within the hepatic vasculature may lead to vasodilation of the parenchyma and lead to greater 72 
surface area for glucose uptake to occur.  However, with ageing there is evidence for both 73 
diminished NO production and impaired vascular responses to NO (49, 52). These age related 74 
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changes may be associated with different responses to nitrate supplementation or other 75 
interventions aimed at increasing NO bioavailability. 76 
Diets rich in vegetables have been shown to have beneficial effects on cardiovascular health 77 
(23), morbidity and mortality (33) and to reduce the risk of developing T2DM (13)  and are 78 
rich in inorganic nitrate. There is growing evidence to suggest nitrate is at least in part 79 
responsible for these beneficial effects (9). Recent reports have described how nitrate 80 
supplementation can reduce systolic and diastolic blood pressure in healthy older adults (30, 81 
34, 35) and in clinical cohorts with elevated cardiovascular risk factors (6, 36, 37, 42). Other 82 
reports have shown no effect of nitrate supplementation on systolic and diastolic blood pressure 83 
in clinical cohorts (2, 24, 58). Although in a overweight and obese group of individuals, nitrate 84 
supplementation has been shown to improve postprandial endothelial function following a 85 
mixed meal (32). Nitric oxide mediates glucose uptake from the intestines (27) and facilitates 86 
its disposal into skeletal muscle in animal models (51) and in individuals with T2DM (38). 87 
Increases in the bioavailability of nitric oxide stimulates insulin secretion (54) and increases 88 
GLUT4 translocation (46). Supplementation of nitrite in the drinking water of eNOS deficient 89 
mice (for 10 weeks) reduces glycated hemoglobin concentrations, and lowers baseline and 90 
postprandial glucose concentrations (12). A study in young adults supplemented with dietary 91 
nitrate has shown a reduction in plasma glucose concentrations post exercise compared to 92 
placebo (67). Recently, another study described a reduction in baseline plasma glucose 93 
concentrations 2.5h after supplementation with pharmacological sodium nitrate in individuals 94 
with T2DM but there was no effect on post prandial glucose concentrations following an oral 95 
glucose tolerance test (14). In contrast, Betteridge et al. (7) showed no change in glucose 96 
kinetics during exercise in a group of recreationally active individuals. Moreover, beetroot 97 
juice taken in conjunction with a 75g glucose load did not augment glucose uptake in 16 obese, 98 
insulin resistant men (21). Another potential mechanism for changes in glucose concentrations 99 
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maybe related to incretins and their insulinotropic effects. Incretin hormones are released from 100 
the small intestine in response to ingestion of food and are a key component in glucose 101 
homeostasis via their insulinotropic effect (28). Incretins mediate the uptake of glucose in the 102 
intestines in an nitric oxide dependent fashion (27) and have been shown to promote the 103 
production of nitric oxide within the portal vein (17).  104 
Purpose / hypothesis  105 
Aging may affect the bioavailability of nitric oxide and thus hepatic diffusion. Therefore we 106 
will assess our outcomes in a young adult and an older adult cohort. The aim of this study was 107 
to assess if inorganic nitrate modulates portal vein flux and velocity and hepatic microvascular 108 
diffusion and secondly to assess if supplementation with nitrate alters post-prandial plasma 109 
glucose, incretin and C-Peptide concentrations and blood pressure. We hypothesised that 110 
supplementation of the diet with dietary nitrate would increase blood flow to the liver and 111 
vasodilate the microvasculature causing improved postprandial glucose uptake.  112 
Materials and Methods 113 
Volunteers    114 
37 individuals (17 healthy young individuals and 20 healthy older adults) provided written 115 
informed consent to participate in this double-blind, placebo-controlled, cross-over design 116 
study (see table 1 for subject characteristics). The healthy young individuals were recruited via 117 
word of mouth. The older adults were recruited via the NIHR Exeter Clinical Research Facility, 118 
Exeter 10,000 cohort. This is a database of individuals who have been pre-screened and 119 
consented to be contacted as research volunteers. The trial commenced in July 2014 and ended 120 
in April 2015. Ethical approval was obtained from the Exeter NRES Committee (14/SW/0092). 121 
This trial was registered on the ClinicalTrials.gov website (NCT02195856). Healthy young 122 
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individuals were recruited if they were aged between 18 and 35 and older adults aged between 123 
50 and 75.  124 
Participants were excluded if they: were unable to consent, took vasoactive medications, had 125 
uncontrolled hypertension (systolic BP> 160 mmHg), received antibiotic therapy within the 126 
preceding two weeks, took regular organic nitrate, thiazolidinidiones or nicorandil, had severe 127 
claustrophobia, were smokers (smoked within past 3 months), had an estimated glomerular 128 
filtration rate (eGFR) <30 ml/min/1.73 m2, had a myocardial infarction or cerebro-vascular 129 
event within the preceding 3 months, had previous brain surgery, had a cardiac pacemaker, had 130 
metal fragments in the eye or larger metal objects that would interfere with data collection or 131 
analysis. Volunteers, who had medical interventions where metal implants were inserted, were 132 
assessed to determine safety in the scanner.  133 
Experimental Overview  134 
Screening and consent took place at the Diabetes and Vascular Research Centre at the NIHR 135 
Exeter Clinical Research Facility. Following screening checks volunteers were randomly 136 
assigned (within their respective age-group) to a double-blind crossover experimental design 137 
to consume 140 ml of nitrate rich beetroot juice (beetroot juice; containing 11.91 mmol of 138 
nitrate; Beet it, James White Drinks Ltd., Ipswich) or nitrate depleted beetroot juice (placebo; 139 
nitrate depleted beetroot juice containing 0.01 mmol of nitrate; Beet it, James White Drinks 140 
Ltd., Ipswich). The placebo production has been detailed previously (25); the final product is 141 
identical in appearance, odour, taste, colour and texture.     142 
On the day of testing, volunteers fasted overnight (from 10pm) although water consumption 143 
was allowed to ensure they arrived in a hydrated state. Volunteers were asked to refrain from 144 
antibacterial mouthwash throughout the study and for at least 7 days prior to experimental 145 
visits. Antibacterial mouthwash has been demonstrated to reduce the concentration of oral 146 
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bacterial anaerobes responsible for the reduction of nitrate in the entero-salivary pathway (26). 147 
Volunteers were also asked to avoid caffeine for 12 hours, alcohol and strenuous activity for 148 
24 hours and nitrate rich foods on the day prior to their visits.       149 
Volunteers arrived at the Exeter Magnetic Resonance Research Centre at the University of 150 
Exeter. A 30 minute acclimatisation period was implemented prior to the magnetic resonance 151 
imaging (MRI) scans. During this acclimatisation period a cannula was inserted in order to take 152 
baseline plasma concentrations for glucose (fluoride & EDTA tubes; Sarstedt, S-Monovette, 153 
Nümbrecht, Germany). Plasma nitrate and nitrite were collected (lithium heparin tubes; 154 
Sarstedt, S-Monovette, Nümbrecht, Germany) and analysis was performed as previously 155 
described (24). Prior to the baseline MRI scan, 5 resting, seated blood pressure (BP) 156 
measurements were taken (Schiller Medical, Wissembourg, France) and an average of the final 157 
3 recorded.  158 
Following the baseline MRI scans the volunteers were provided with either the nitrate rich 159 
beetroot juice or the placebo with two slices of toast, butter and jam. The combined quantity 160 
of carbohydrate equated to 76 grams and is approximately equivalent to that that would be 161 
consumed during an oral glucose tolerance test (4). Every hour, for three subsequent hours, 162 
from the consumption of the beetroot juice, another set of scans were performed. Immediately 163 
prior to each scan brachial artery blood pressure and venous blood samples were taken and 164 
processed as previously described. A minimum 7 day washout period between the crossover 165 
was employed.     166 
MRI scans      167 
A 1.5 T (Philips, Amsterdam, The Netherlands) magnetic resonance imaging (MRI) scanner 168 
was used in order to examine changes in velocity and flux in the portal vein and microvascular 169 
diffusion in the posterior right lobe of the liver.  170 
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Initial structural images were obtained to orientate the portal vein and an 8mm slice was 171 
selected perpendicular to the long axis of the vein. To determine flux and velocity a cardiac 172 
triggered velocity sensitive phase encoding imaging sequence (22) was employed which 173 
obtained image data at 20 time points throughout the cardiac cycle. Analysis of the portal vein 174 
was subsequently undertaken using a package supplied as part of the general scanner software. 175 
For each separate measurement the circumference of the vessel was manually drawn and 176 
recorded for each of the 20 time points to establish a defined region of interest (ROI). Within 177 
this ROI, flow and velocity were automatically calculated to give profiles throughout the 178 
cardiac cycle. A mean across the cardiac cycle for flux and velocity was created. Day to day 179 
repeatability for portal vein velocity and flux was assessed in 6 individuals studied on two 180 
occasions and was 16% and 13% respectively.  181 
To examine the microvascular diffusion in the posterior right lobe of the liver, a magnetic 182 
resonance sequence sensitive to flow was employed via the application of magnetic field 183 
gradients in three orthogonal directions. Microvascular diffusion was averaged over all 184 
directions within the region of interest and is known as the apparent diffusion coefficient 185 
(ADC). Day to day repeatability was assessed in 6 individuals on two days for ADC (1 ROI: 186 
ADC = 1.15 ± 0.12, CV = 9.77%) and with multiple ROI. One ROI away from any major 187 
vessels had greater repeatability than 2, 3 and 6 sites (2 ROI: ADC = 1.11 ± 0.21, CV = 15.29%; 188 
3 ROI: ADC = 1.10 ± 0.23, CV = 21.34%; 6 ROI: ADC = 1.09 ± 0.33, CV = 30.32%). To 189 
calculate ADC within the posterior left lobe of the liver, a ROI (typically 2500 mm3) was 190 
manually drawn using the scanner software and the signal intensity within determined. For 191 
multiple ROI during repeatability testing, different locations within the posterior left lobe of 192 
the liver were selected. Each selection was in the same approximate location for each 193 
individual. ADC was subsequently calculated based upon the ratio of signal intensity from the 194 
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two images generated from the MR sequence employed, one of which was sensitive to flow, 195 
whereas the other had a low sensitivity to flow, where:  196 
ADC= -1/(b1-b0)  Ln (S0/S1) 197 
S0 is the signal intensity in the low flow sensitivity image  198 
S1 is the signal intensity in the flow sensitive image  199 
b0 is the magnetic field gradient used in the low flow sensitivity image=250 s/mm
2 200 
b1 is the magnetic field gradient used in the flow sensitive image=750 s/mm
2. 201 
Incretin and C-Peptide analysis 202 
To preserve total and active glucagon-like peptide-1 (GLP-1) for analysis, 10µl of dipeptidyl 203 
peptidase 4 inhibitor (Merck Millipore, Darmstadt, Germany) per 1ml of whole blood was 204 
injected into ice-chilled EDTA tubes (Sarstedt, S-Monovette, Nümbrecht, Germany) prior to 205 
adding the blood. Samples were immediately centrifuged at 3600 rpm for 10 minutes at 4°C, 206 
plasma was aliquoted and flash frozen with liquid nitrogen. Quantification of total and active 207 
GLP-1 were performed using an enzymatic immunoassay (Total and Active GLP-1 kits; MSD, 208 
Rockville, MD, USA). The inter-assay variation for total and active GLP-1 was 9.7% and 209 
11.3% respectively.  210 
C-peptide quantification was performed using a Roche E170 analyser (Roche Diagnostics, 211 
Mannheim, Germany). The assay utilised a direct electrochemiluminescence immunoassay 212 
with mouse monoclonal antibodies which were coupled to the paramagnetic particles. Venous 213 
blood samples were taken into ice chilled GEL Serum tubes (Sarstedt, S-Monovette, 214 
Nümbrecht, Germany). Samples were immediately centrifuged at 3600 rpm for 10 minutes at 215 
4°C, aliquoted and stored at -80°C.  216 
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Sample size and randomisation 217 
The ADC was our primary outcome. No study to date has assessed the effect of dietary nitrate 218 
supplementation on liver diffusion. Therefore, no data was available to power our outcome. 219 
For 90% power with an α-level set at P = 0.05 (two tailed), to detect a 1 SD difference, 13 220 
volunteers were required to compare within group for placebo and active conditions. For 80% 221 
power with an α-level set at P = 0.05 (two tailed), to detect a 1.05 SD difference, 16 volunteers 222 
were required to compare between groups for placebo and active conditions.  223 
Data and statistical analysis 224 
All data were tested for normality. Where data were not normally distributed a non-parametric 225 
test was performed. Data are presented as means ± standard deviation (SD). Statistical analyses 226 
were performed on SPSS software version 21.0 (Chicago, IL, USA). Statistical difference was 227 
accepted when P < 0.05. Statistical differences were assessed using repeated measures 228 
ANOVAs. Where baseline differences were present, ANCOVAs were used with baseline as a 229 
covariate. For age comparisons, group was used as a covariate.  Where statistic differences 230 
were present post hoc (Bonferroni corrected) analysis were performed.  231 
Results  232 
37 individuals (17 healthy young individuals and 20 healthy older adults) gave written 233 
informed consent to participate. Post screening and consent 6 individuals were withdrawn from 234 
the trial. 1 individual had abnormal liver function, 1 had a metal pin (in an area which would 235 
interfere with data collection) and 4 had previously undiagnosed claustrophobia. 31 individuals 236 
(16 healthy young individuals and 15 healthy older adults) were randomised to start in either 237 
the nitrate rich beetroot arm or the placebo arm. No differences between dietary intake or 238 
exercise patterns were recorded prior to both study visits. The beetroot juice was well tolerated 239 
and no adverse events were reported.  240 
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Plasma nitrate concentration:  241 
Supplementation with inorganic dietary nitrate caused an increase in plasma nitrate 242 
concentration compared to placebo see figure 1. The elevated plasma nitrate concentration was 243 
maintained for the entire testing period. Post hoc analysis revealed no significant differences 244 
at baseline (prior to any supplementation on the placebo and the nitrate rich juice arm of the 245 
study) for plasma nitrate concentration (young adults: mean difference; 2 ± 4.4 µM, P = 0.64, 246 
95% CI -7.4, 11.5; older adults: mean difference; 1.5 ± 4.1 µM, P = 0.72, 95% CI -10.4, 7.4). 247 
Post hoc analysis revealed a significant increase when beetroot juice was compared with 248 
placebo at 1 hour post supplementation (young adult: mean difference; 543 ± 37 µM, P < 0.001, 249 
95% CI 463, 624; older adult: mean difference; 505 ± 39 µM, P < 0.001, 95% CI 420, 590), 2 250 
hours post (young adult: mean difference; 645 ± 29 µM, P < 0.001, 95% CI 581, 707; older 251 
adult: mean difference; 632 ± 35 µM, P < 0.001, 95% CI 556, 710) and 3 hours post (young 252 
adult: mean difference; 598 ± 31 µM, P < 0.001, 95% CI 530, 665; older adult: mean difference; 253 
616 ± 26 µM, P < 0.001, 95% CI 559, 673). No statistical difference was present for the young 254 
adult group compared to the older adult group for nitrate concentration (F(1, 25) = .1, P = 0.75).  255 
Plasma nitrite concentration:  256 
Supplementation with inorganic dietary nitrate caused an increase in plasma nitrite 257 
concentration compared to placebo see figure 1. This increase was faster in older adults, 258 
compared to young adults (F(3, 75) = 2.93, P = 0.039). The elevated plasma nitrite concentration 259 
was maintained for the entire testing period. Post hoc analysis revealed no significant 260 
differences at baseline (prior to any supplementation on the placebo and the nitrate rich juice 261 
arm of the study) for plasma nitrite concentration (young adults: mean difference; -3.3 ± 74 262 
nM, P = 0.86, 95% CI -43, 36; older adults: mean difference; 26.5 ± 78 nM, P = 0.21, 95% CI 263 
-17, 69). Post hoc analysis revealed  a significant increase when beetroot juice was compared 264 
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with placebo at 1 hour post supplementation (young adults: mean difference; 283 ± 201 nM, P 265 
< 0.001, 95% CI 176, 391: older adults: mean difference; 471 ± 381 nM, P < 0.001, 95% CI 266 
260, 682), 2 hours post (young adults: mean difference; 497 ± 259 nM, P < 0.001, 95% CI 353, 267 
640: older adults: mean difference; 545 ± 325 nM, P < 0.001, 95% CI 364, 325) and 3 hours 268 
post (young adults: mean difference; 559 ± 201 nM, P < 0.001, 95% CI 442, 675: older adults: 269 
mean difference; 797 ± 525 nM, P < 0.001, 95% CI 493, 1100). There was also a significant 270 
increase at peak plasma nitrite concentration (hour 3), compared with hour 2 (mean difference; 271 
201 ± 344 nM, P = 0.039, 95% CI 11, 392). 272 
ADC:  273 
There was no effect of supplementation (absolute; young adults: F(1, 15) = .314, P = 0.58; older 274 
adults; F(1, 14) = 1.65, P = 0.22; change from baseline; young adults: F(1, 15) = .701, P = 0.42; 275 
older adults; F(1, 14) = 2.91, P = 0.11) or an interaction effect (time by supplement) when 276 
comparing supplementation with inorganic dietary nitrate on hepatic diffusion compared to 277 
placebo (absolute; young adults: F(3, 45) = 0.25, P = 0.74; older adults; F(3, 42) = 1.3, P = 0.28; 278 
change from baseline; F(2, 30) = 0.13, P = 0.67; older adults; F(2, 28) = 0.45, P = 0.64). See figure 279 
2 for details.   280 
Portal Vein Flux:  281 
There was a baseline difference for the older adults cohort (older adults: placebo; 14.6 ± 4.3 282 
vs. beetroot juice; 11.7 ± 2.9 ml/s, P = 0.04, 95% CI -5.67, -0.13) but not in the young adults. 283 
See figure 3. Therefore, data were analysed using ANCOVA for the older adult cohort. There 284 
was no supplementation (absolute; young adults: F(1, 15) = 1.00, P = 0.33; older adults; F(1, 12) = 285 
1.28, P = 0.28; or interaction effect (young adults: F(3, 45) = 0.34, P = 0.79; older adults: F(2, 24) 286 
= 0.68, P = 0.52) when comparing supplementation with inorganic dietary nitrate on portal 287 
vein flux compared to placebo. 288 
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Portal Vein Velocity: 289 
There was a baseline difference for the older adults cohort (older adults: placebo; 13 ± 3.4 vs. 290 
beetroot; 11.1 ± 3 cm/s, P = 0.04, 95% CI -3.7, -1.1) but not in the young adults. See figure 3. 291 
Therefore, data were analysed using ANCOVA for the older adult cohort.  Portal vein velocity 292 
was decreased following beetroot juice, compared to placebo juice for the young adults: (F(1, 293 
15) = 2.9, P = 0.04; however, no effect was seen in the older adults (F(2, 24) = 0.84, P = 0.44). 294 
Plasma glucose concentration:  295 
There was a baseline difference for the older adults cohort (older adults: placebo; 5.3 ± 0.4 vs. 296 
beetroot; 5.1 ± 0.4 cm/s, P = 0.02, 95% CI -3.6, -0.04) but not in the young adults. See figure 297 
4. Therefore, data were analysed using ANCOVA for the older adult cohort. No effect of 298 
supplementation (young adults: F(1, 15) = 0.96, P = 0.35; older adults; F(1, 12) = 1.4, P = 0.25) or 299 
an interaction effect was present when comparing supplementation with inorganic dietary 300 
nitrate on plasma glucose concentrations compared to placebo (young adults: F(3, 45) = 0.96, P 301 
= 0.42; older adults: F(3, 42) = 1.07, P = 0.36). See figure 4.  302 
Effects on incretins and C-Peptide:  303 
There was no effect of supplementation (young adults: F(1, 15) = 0.48, P = 0.49; older adults; 304 
F(1, 13) = 0.26, P = 0.62) or an interaction effect when comparing supplementation with 305 
inorganic dietary nitrate on total GLP-1concentrations compared to placebo (young adults: F(2, 306 
30) = 0.81, P = 0.45; older adults: F(2, 26) = 1.63, P = 0.22),  active GLP-1 concentrations (young 307 
adults: F(2, 30) = 0.85, P = 0.43; older adults: F(2, 24) = 0.67, P = 0.09) or C-peptide (young adults: 308 
F(3, 45) = 0.79, P = 0.50; older adults: F(3, 42) = 0.39, P = 0.76). See figure 5.  309 
Effects on resting blood pressure:  310 
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There was no effect of supplementation (young adults: F(1, 15) = 1.2, P = 0.28; older adults; F(1, 311 
14) = 1.7, P = 0.20) or an interaction effect when comparing supplementation with inorganic 312 
dietary nitrate on systolic blood pressure compared to placebo (young adults: F(3, 45) = 0.20, P 313 
= 0.89; older adults: F(3, 42) = 1.7, P = 0.18) or diastolic blood pressure for supplementation 314 
(young adults: F(1, 15) = 2.6, P = 0.13; older adults: F(1, 14) = 4.0, P = 0.06) or an interaction 315 
(young adults: F(3, 45) = 0.25, P = 0.86; older adults: F(3, 42) = 0.45, P = 0.72). See figure 6.  316 
Discussion  317 
This is the first study to investigate the effects of dietary nitrate supplementation on hepatic 318 
blood flow, incretin and C-peptide concentrations in young and older adults. The primary 319 
outcomes were to assess changes in microvascular diffusion (ADC), portal vein flux and 320 
velocity. Nitrate supplementation increased plasma nitrate and nitrite in both the young and 321 
older individuals but did not alter portal vein flux, or affect ADC. There was however, an 322 
interaction effect in the young adults, however, no effect was present in the older adults 323 
between visits for portal vein velocity. Secondary outcomes were to assess plasma glucose, 324 
incretin, C-peptide concentrations and blood pressure changes. Nitrate supplementation did not 325 
alter plasma glucose, incretin or C-peptide concentration and the response was not different in 326 
young compared to older individuals. Nitrate supplementation did not lower systolic or 327 
diastolic blood pressure in young or older individuals.       328 
Nitrate supplementation and plasma nitrate and plasma nitrite concentration.  329 
Plasma nitrate concentration peaked (~2000%) at 2 hours post nitrate rich beetroot juice 330 
compared with placebo for both the young and older adult groups. Similarly, plasma nitrite 331 
concentration rose following nitrate rich beetroot juice compared to the placebo and peaked at 332 
2 hours for the young group and was highest at 3 hours for the older adult group representing 333 
a ~230 and 460% increase, respectively. The pharmacokinetic response for both plasma nitrate 334 
A 
B 
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and nitrite concentrations of both cohorts are similar to a previously reported dose response 335 
study in young healthy individuals (66). However, the pharmacokinetic response of plasma 336 
nitrate and nitrite concentrations have not previously been reported in a group of healthy older 337 
adults. Kelly et al. (35) recently reported a rise in plasma nitrite concentration of a similar 338 
magnitude of 418% in a group of healthy older adults.  339 
Nitrate supplementation and hepatic blood flow  340 
Despite a statistically significant and physiologically meaningful rise in plasma nitrite 341 
concentration, this did not lead to an increase in microvascular diffusion (ADC) or portal vein 342 
flux. There was however, an interaction effect for the young adults for a reduction in portal 343 
vein velocity. The portal vein supplies 75% of inflow, with the remainder supplied by the 344 
hepatic artery (56) and though the blood it supplies is partially deoxygenated, the portal vein  345 
supplies ~50% of the liver’s O2 delivery (See (29, 62) for reviews). A higher concentration of 346 
deoxyhaemoglobin may lead to a faster conversion of nitrite to nitric oxide (16) in the portal 347 
vein. It is therefore likely that the highest concentrations of nitric oxide and plasma glucose 348 
concentrations would be found in the liver. There was a statistical difference in the older adult 349 
cohort for baseline portal vein flux and velocity on the two visits. This study was powered to 350 
detect a 1 SD change in our primary outcome, ADC, and as portal vein flux and velocity had 351 
poorer reproducibility this may have contributed to the apparent baseline differences. The mean 352 
interaction change for portal vein velocity is -0.81 ± 3, in a similarly designed study we would 353 
need to recruit 291 individuals to see this effect.   354 
Nitrate supplementation and plasma glucose C -peptide and Incretin concentrations  355 
There was no significant difference between active or placebo juice for plasma glucose 356 
concentration. It should be noted that in the older adult cohort there was a statistically 357 
significant baseline difference in plasma glucose concentration (mean difference = -0.2 mmol/l 358 
16 
 
or 3.8%) on the placebo and nitrate rich supplementation day. Given the order of the two arms 359 
was randomised this was unlikely to be due to carry over effect from the previous 360 
supplementation period. Nitric oxide has been shown to mediate glucose uptake from the 361 
intestines and mediate glucose uptake into skeletal muscle (27, 38, 51), Potential mechanisms 362 
for this include an elevated nitric oxide bioavailability which in turn may stimulate insulin 363 
secretion (54) and increase GLUT4 translocation (46). Increased levels of GLP-1 have been 364 
shown to slow gastric emptying and reduce levels of satiety which may have significant health 365 
benefits by controlling food intake (68). Increasing these incretin concentrations may also 366 
lower plasma glucose concentrations via their insulinotropic effects. This would be particularly 367 
important in individuals with T2DM as they have an impaired incretin response (53). Although 368 
there was no statistical difference for the active or total GLP-1 concentration there was a trend 369 
for an increase in plasma concentration of active GLP-1’s in the older adult cohort in the active 370 
arm (mean difference 0.55±0.86 pg/ml representing a 32.5% increase; see figure 5, D). If this 371 
represents a real difference we would require 41 participants in order to detect this change. 372 
Further analysis is warranted in an older adult population. Despite this, no such trend was 373 
evident between the active or placebo juice for C-peptide concentrations. Beetroot juice has 374 
been shown to lower the postprandial insulin response in healthy adults; however, it is unclear 375 
whether this is due to nitric oxide, polyphenols or betalains (65). Results from the present study 376 
with a true placebo would suggest that nitric oxide is not the active ingredient and further 377 
exploration of antioxidants and polyphenols in this area are warranted.  378 
Nitrate supplementation and resting blood pressure. 379 
There was no significant difference in systolic or diastolic BP following nitrate rich beetroot 380 
juice supplementation (at peak plasma nitrite concentration) compared to placebo in the healthy 381 
young adult cohort. This is similar to some acute nitrate supplementation studies (15, 57, 64). 382 
However, most studies have shown hypotensive effects with acute supplementation regimens 383 
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(40, 41, 60, 61, 63). There was no significant reduction in systolic BP following nitrate rich 384 
beetroot juice compared to placebo in the healthy older adult cohort. We report a non-385 
significant 5 mm Hg drop in systolic BP. Kelly et al. (35) report a statistically significant 5 386 
mmHg drop in systolic BP, whilst another groups reported larger reductions (30). Another 387 
study in healthy older adults also reported no effect of nitrate supplementation on systolic BP 388 
(8). A detailed pharmacokinetic study in healthy older adults over a prolonged period may 389 
identify at what time peak plasma nitrite concentrations occur. If the pharmacokinetic response 390 
of plasma nitrite concentrations in the healthy older adult group continued to rise past 3 hours, 391 
a greater hypotensive effect than measured here may have occurred. However, a dose response 392 
study of young adults showed the elevation in plasma nitrite concentration described above 393 
was sufficient to cause a drop in systolic and diastolic blood pressure (66).  394 
Strengths and limitations 395 
This is the first study to examine the effect of nitrate supplementation on hepatic blood flow. 396 
This study has a robust experimental design as a double-blind, placebo controlled, crossover 397 
trial. A limitation to this study is that we did not measure plasma nitrite concentration beyond 398 
3 hours supplementation. Future research should aim to elucidate if plasma nitrite concentration 399 
rises beyond 3 hours in healthy older adults. The study was powered to detect a change of 1 400 
SD in the outcome measures, changes smaller than this may have occurred but not been noted 401 
as significant. Finally, variability in our baseline measurement from the MRI analysis were 402 
more than anticipated, however, analysis was performed on absolute and change from baseline, 403 
therefore, this should not be a significant impediment.  404 
Conclusion 405 
This was the first study to examine the hepatic blood flow response to nitrate supplementation. 406 
Despite physiologically meaningful elevation in plasma nitrite concentration following an 407 
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acute dose of 11.91 mmol of nitrate, there was no effect on hepatic blood flow, plasma glucose, 408 
incretin, C-peptide concentrations or systolic and diastolic blood pressure for young or older 409 
adults.  410 
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Figure Legends 614 
Figure 1. Plasma nitrate and nitrite concentration. Figures depict changes across time for 615 
beetroot and placebo juice. The open circles are placebo and the closed circles beetroot. A and 616 
B: young adult cohort and C and D shows the older adult cohort. The * represents a significant 617 
difference when beetroot juice is compared with placebo < 0.001. The # shows a significant 618 
difference in the beetroot condition when hour 2 is compared to hour 3.  619 
Figure 2. Microvascular diffusion. Figure shows ADC changes across time for beetroot and 620 
placebo juice. A: young adult cohort and B: older adult cohort. The open circles are placebo 621 
and the closed circles beetroot.  622 
Figure 3. Portal vein flux and Portal vein velocity. Figures depict changes across time for 623 
beetroot and placebo. A and B: young adult cohort and C and D shows the older adult cohort. 624 
The open circles are placebo and the closed circles beetroot. The * represents a statistically 625 
different baseline portal vein flux between conditions. 626 
Figure 4. Plasma glucose and C-peptide concentration. Figures depict changes across time for 627 
beetroot and placebo juice. A and B: young adult cohort and C and D shows the older adult 628 
cohort. The open circles are placebo and the closed circles beetroot. The * represents a 629 
statistically different baseline glucose concentration between conditions. 630 
Figure 5. Total GLP-1 and active GLP-1 concentration. Figures depict changes across time for 631 
beetroot and placebo juice. A and B: young adult cohort and C and D shows the older adult 632 
cohort. The open circles are placebo and the closed circles beetroot. 633 
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Figure 6. Systolic blood pressure and diastolic blood pressure. Figures depict changes across 634 
time for beetroot and placebo juice. A and B: young adult cohort and C and D shows the older 635 
adult cohort. The open circles are placebo and the closed circles beetroot.  636 
Table legends.  637 
Table 1. Participant characteristics included in the final analysis.      638 
